Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Nizar M TannirSabina SignorettiToni K ChoueiriDavid F McDermottRobert J MotzerAbdallah FlaifelJean-Christophe PignonMiriam FicialOsvaldo Arén FronteraSaby GeorgeThomas PowlesFrede DonskovMichael R HarrisonPhilippe BarthélémyScott S TykodiJudit KocsisAlain RavaudJeronimo R Rodriguez-CidSumanta K PalAndre M MuradYuko IshiiShruti Shally SaggiM Brent McHenryBrian I RiniPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
NIVO+IPI showed unprecedented long-term survival, response, and complete response benefits versus sunitinib in previously untreated patients with sRCC and intermediate/poor-risk disease, supporting the use of first-line NIVO+IPI for this population.See related commentary by Hwang et al., p. 5.